198 related articles for article (PubMed ID: 21983624)
1. Hybridization of conditional and predictive power for futility assessment in sequential clinical trials with time-to-event outcomes: a resampling approach.
Yi J; Fang L; Su Z
Contemp Clin Trials; 2012 Jan; 33(1):138-42. PubMed ID: 21983624
[TBL] [Abstract][Full Text] [Related]
2. A flexible futility monitoring method with time-varying conditional power boundary.
Ying Zhang ; Clarke WR
Clin Trials; 2010 Jun; 7(3):209-18. PubMed ID: 20423927
[TBL] [Abstract][Full Text] [Related]
3. Assessment of futility in clinical trials.
Snapinn S; Chen MG; Jiang Q; Koutsoukos T
Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
[TBL] [Abstract][Full Text] [Related]
4. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
5. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
Lachin JM
Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
[TBL] [Abstract][Full Text] [Related]
6. Pro/con clinical debate: It is acceptable to stop large multicentre randomized controlled trials at interim analysis for futility. Pro: Futility stopping can speed up the development of effective treatments.
Schoenfeld DA
Crit Care; 2005 Feb; 9(1):34-6; discussion 34-6. PubMed ID: 15693981
[TBL] [Abstract][Full Text] [Related]
7. Alternative views on setting clinical trial futility criteria.
Gallo P; Mao L; Shih VH
J Biopharm Stat; 2014; 24(5):976-93. PubMed ID: 24933121
[TBL] [Abstract][Full Text] [Related]
8. A new futility test approach in clinical interim data monitoring.
Xue D
Pharm Stat; 2012; 11(6):468-75. PubMed ID: 23015479
[TBL] [Abstract][Full Text] [Related]
9. Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility.
Walter SD; Han H; Briel M; Guyatt GH
Stat Med; 2017 Apr; 36(9):1506-1518. PubMed ID: 28183155
[TBL] [Abstract][Full Text] [Related]
10. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
Schmidt R; Burkhardt B; Faldum A
Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
[TBL] [Abstract][Full Text] [Related]
11. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
Lachin JM
Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
[TBL] [Abstract][Full Text] [Related]
12. Pro/con clinical debate: It is acceptable to stop large multicentre randomized controlled trials at interim analysis for futility. Con: the hazards of stopping for futility.
Meade MO
Crit Care; 2005 Feb; 9(1):34-6; discussion 34-6. PubMed ID: 15717419
[No Abstract] [Full Text] [Related]
13. A systematic survey of randomised trials that stopped early for reasons of futility.
Walter SD; Han H; Guyatt GH; Bassler D; Bhatnagar N; Gloy V; Schandelmaier S; Briel M
BMC Med Res Methodol; 2020 Jan; 20(1):10. PubMed ID: 31948397
[TBL] [Abstract][Full Text] [Related]
14. Choice of futility boundaries for group sequential designs with two endpoints.
Schüler S; Kieser M; Rauch G
BMC Med Res Methodol; 2017 Aug; 17(1):119. PubMed ID: 28789615
[TBL] [Abstract][Full Text] [Related]
15. Optimal Futility Interim Design: A Predictive Probability of Success Approach with Time-to-Event Endpoint.
Tang Z
J Biopharm Stat; 2015; 25(6):1312-9. PubMed ID: 25379701
[TBL] [Abstract][Full Text] [Related]
16. Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpoint.
Li X; Herrmann C; Rauch G
BMC Med Res Methodol; 2020 Nov; 20(1):274. PubMed ID: 33153438
[TBL] [Abstract][Full Text] [Related]
17. Informing the selection of futility stopping thresholds: case study from a late-phase clinical trial.
Hughes S; Cuffe RL; Lieftucht A; Garrett Nichols W
Pharm Stat; 2009; 8(1):25-37. PubMed ID: 18383194
[TBL] [Abstract][Full Text] [Related]
18. A general inefficacy interim monitoring rule for randomized clinical trials.
Freidlin B; Korn EL; Gray R
Clin Trials; 2010 Jun; 7(3):197-208. PubMed ID: 20423925
[TBL] [Abstract][Full Text] [Related]
19. Test and power considerations for multiple endpoint analyses using sequentially rejective graphical procedures.
Bretz F; Maurer W; Hommel G
Stat Med; 2011 Jun; 30(13):1489-501. PubMed ID: 21290405
[TBL] [Abstract][Full Text] [Related]
20. Upstrapping to determine futility: predicting future outcomes nonparametrically from past data.
Wild JL; Ginde AA; Lindsell CJ; Kaizer AM
Trials; 2024 May; 25(1):312. PubMed ID: 38725072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
